Intracellular cytokine patterns in Behçet's disease in comparison to ankylosing spondylitis - Influence of treatment with interferon-α2a

Clinical and Experimental Rheumatology

Volumn 25, Issue 4 SUPPL. 45, 2007, Pages

  Amberger, Michaela ^a   Groll, Stefanie ^a   Günaydin, Ilhan ^a   Deuter, Christoph ^b   Vonthein, Reinhard ^a   Kötter, Ina ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Department of Ophthalmology I ^*  (Germany)

Author keywords

Ankylosing spondylitis; Beh et's disease; IFN 2a; Intracellular cytokines

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COLCHICINE; CYCLOSPORIN A; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; INTERLEUKIN 4; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; CELL PROTEIN; CELL SURFACE MARKER; CYTOKINE; GAMMA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; LOW DRUG DOSE; MALE; MONOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; HUMAN CELL; IMMUNOFLUORESCENCE TEST; T LYMPHOCYTE;

ADULT; ANTIGENS, CD3; BEHCET SYNDROME; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON ALFA-2A; INTERFERON TYPE II; INTERLEUKIN-2; MALE; SPONDYLITIS, ANKYLOSING; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35448956883     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. INTERNATIONAL STUDY GROUP FOR BEHÇET'S DISEASE: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
2. KÖTFER I, GUNAYDIN I, ZIERHUT M, STUBIGER N: The use of interferon alpha in Behçet disease: Review of the literature. Semin Arthritis Rheum 2004; 33: 320-35.
3. SUGI-IKAI N, NAKAZAWA M, NAKAMURA S, OHNO S, MINAMI M: Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci 1998; 39: 996-1004.
4. FRASSANITO MA, DAMMACCO R, CAFFORIO P, DAMMACCO F: Th1 polarization of the immune response in Behçet's disease: A putative pathogenetic role of interleukin-12. Arthritis Rheum 1999; 42: 1967-74.
5. FREYSDOTTIR J, LAU S, FORTUNE F: Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118: 451-7.
6. GÜL A: Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001; 19: S6-12.
7. HAMZAOUI K, HAMZAOUI A, GUEMIRA F, BESSIOUD M, HAMZA M, AYED K: Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205-10.
8. MEGE JL, DILSEN N, SANGUEDOLCE V et al.: Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9.
9. YAMASHITA N: Hyperreactivity of neutrophils and abnormal T cell homeostasis: A new insight for pathogenesis of Behçet's disease. Int Rev Immunol 1997; 14: 11-9.
10. SAYINALP N, OZCEBE OI, OZDEMIR O, HAZNEDAROGLU IC, DUNDAR S, KIRAZLI S: Cytokines in Behçet's disease. J Rheumatol 1996; 23:321-2.
11. KÖTTER I, KOCH S, VONTHEIN R et al.: Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 2005; 23: S20-6.
12. BENEZRA D, FORRESTER JV, NUSSENBLATT RB: Uveitis scoring system: Springer Verlag, Berlin, 1991.
13. KÖTTER I, ZIERHUT M, ECKSTEIN AK et al.: Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87:423-31.
14. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
15. TREUSCH M, VONTHEIN R, BAUR M et al.: Influence of human recombinant interferon-alpha2a on altered lymphocyte subpopulations and monocytes in Behçet's Disease. Rheumatology 2004; 43: 1275-83.
16. RUDWALEIT M, SIEGERT S, YIN Z et al.: Low T cell production of TNF-alpha and IFN-gamma in ankylosing spondylitis: Its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001; 60: 36-42.
17. + T cells. J Exp Med 1993; 178: 1655-63.
18. O'SHEA JJ, MA A, LIPSKY P: Cytokines and autoimmunity. Nat Rev Immunol 2002; 2: 37-45.
19. YAMASHITA N, KANEOKA H, KANEKO S et al.: Role of gammadelta T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997; 107: 241-7.
20. BAETEN D, VAN DAMME N, VAN DEN BOSCH F et al.: Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNF-alpha. Ann Rheum Dis 2001; 60: 750-55.
21. BAETEN D, DE KEYSER F, VAN DAMME N, VEYS EM, MIELANTS H: Influence of the gut and cytokine patterns in spondyloarthropathy. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S38-S42.
22. VAN DAMME N, DE VOS M, BAETEN D et al.: Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 2001; 60: 495-9.
23. SAKANE T, SUZUKI N, UEDA Y et al.: Analysis of interleukin-2 activity in patients with Behçet's disease. Ability of T cells to produce and respond to interleukin-2. Arthritis Rheum 1986; 29: 371-8.
24. RAZIUDDIN S, AL-DALAAN A, BAHABRI S, SIRAJ AK, AL-SEDAIRY S: Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998; 25: 329-33.
25. HORAK I, LOHLER J, MA A,ASMITH KA: Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995; 148: 35-44.
26. REFAELI Y, VAN PARIJS L, ABBAS AK: Genetic models of abnormal apoptosis in lymphocytes. Immunol Rev 1999; 169: 273-82.
27. MALEK TR, BAYER AL: Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4: 665-74.